Dexmedetomidine for sedation of mechanically ventilated neurocritical care patients after head injury

Safety and efficacy of dexmedetomidine as adjuvant to fentanyl/midazolam combination for sedation of mechanically ventilated neurocritical care patients after head injury: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202110584772902

Enrollment

Registered

2021-10-04

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases Respiratory Anaesthesia

Interventions

control group

Dexmedetomidine group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age: 18 - 70 years-old GCS: 8 - 12 at the time of admission

Exclusion criteria

Exclusion criteria: Severe head injury (GCS less than 8) 2. Any previous neurological insult 3. Severe brain edema or brain hemorrhage with midline shift 4. Severe polytrauma 5. Advanced liver or kidney disease 6. Uncontrolled diabetes, hypertension, or heart disease 7. History of chronic use of sedatives, narcotics, alcohol, or drug abuse

Design outcomes

Primary

Measure	Time frame
The number of patient-ventilator asynchrony per day	—

Secondary

Measure	Time frame
Level of sedation by the RASS score. 2. Mean arterial blood pressure. 3. Heart rate. 4. Respiratory rate. 5. Exhaled tidal volume. 6. End tidal CO2. 7. Duration of mechanical ventilation. 8. The NCCU duration of stay.	—

Countries

Egypt

Contacts

Public Contactwalaa elsabeeny

lecturer at national cancer institute cairo university

walaa.elsabeeny@nci.cu.edu.eg00201007798466

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026